|
|
|
|
| LEADER |
03259nmm a2200325 u 4500 |
| 001 |
EB000362178 |
| 003 |
EBX01000000000000000215230 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
130626 ||| eng |
| 020 |
|
|
|a 9781441963062
|
| 100 |
1 |
|
|a Raffa, Robert B.
|e [editor]
|
| 245 |
0 |
0 |
|a Chemo Fog
|h Elektronische Ressource
|b Cancer Chemotherapy-Related Cognitive Impairment
|c edited by Robert B. Raffa, Ronald J. Tallarida
|
| 250 |
|
|
|a 1st ed. 2010
|
| 260 |
|
|
|a New York, NY
|b Springer New York
|c 2010, 2010
|
| 300 |
|
|
|a XXI, 216 p
|b online resource
|
| 505 |
0 |
|
|a Short Introduction and History -- Patient’s Perspective -- Oncology Nurse’s Perspective -- Oncology Pharmacist’s Perspective -- The Impact of Chemo Brain on the Patient with a High-Grade Glioma -- Neurocognitive Effects of Childhood Cancer Treatment -- The Economic Burden -- Designing Conceptual Model-Based Research in Chemotherapy-Related Changes in Cognitive Function -- Neuropsychologic Testing for Chemotherapy-Related Cognitive Impairment -- Imaging as a Means of Studying Chemotherapy-Related Cognitive Impairment -- Chemotherapy Associated Central Nervous System Damage -- Is Systemic Anti-Cancer Therapy Neurotoxic? Does Chemo Brain Exist? And Should We Rename It? -- Evaluation of Multiple Neurotoxic Outcomes in Cancer Chemotherapy -- Chemotherapy-Related Visual System Toxicity -- The Possible Role of Cytokines in Chemotherapy-Induced Cognitive Deficits -- Pharmacokinetics of Anti-Cancer Drugs Used in Breast Cancer Chemotherapy -- Combination Analysis -- Animal Models -- Chemo Brain (Chemo Fog) as a Potential Side Effect of Doxorubicin Administration: Role of Cytokine-Induced, Oxidative/Nitrosative Stress in Cognitive Dysfunction -- Effects of 5-FU -- Future Directions
|
| 653 |
|
|
|a Medicine / Research
|
| 653 |
|
|
|a Biology / Research
|
| 653 |
|
|
|a Cancer
|
| 653 |
|
|
|a Biomedical Research
|
| 653 |
|
|
|a Cancer Biology
|
| 700 |
1 |
|
|a Tallarida, Ronald J.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Advances in Experimental Medicine and Biology
|
| 028 |
5 |
0 |
|a 10.1007/978-1-4419-6306-2
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4419-6306-2?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 610.72
|
| 520 |
|
|
|a Cancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. Due to the advances in chemotherapy and other aspects of prevention, early detection, and treatment modalities, an increasing percentage of patients are surviving the disease. For some types of cancer, the majority of patients live decades beyond their diagnosis. For this they are forever thankful and appreciative of the drugs that helped lead to this increased survival rate. But no drug is devoid of adverse effects. This also applies to chemotherapeutic agents. The acute cytotoxic effects of these agents are well known––indeed are often required for their therapeutic benefit. The chronic adverse effects are varied and in some cases less well known. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects
|